[acb-diabetics] significant breakthrough on type 2

[Patricia LaFrance-Wolf]

This article originally posted 15 September, 2010 and appeared in
<http://www.diabetesincontrol.com/topics/medication> Medication,
<http://www.diabetesincontrol.com/diabetes-in-control-newsletters/blood-gluc
ose-control> Blood Glucose Control,
<http://www.diabetesincontrol.com/topics/type-2-diabetes> Type 2 Diabetes,
<http://www.diabetesincontrol.com/diabetes-in-control-newsletters/prevention
> Prevention,
<http://www.diabetesincontrol.com/diabetes-in-control-newsletters/539> Issue
539 

 



Significant Type 2 Diabetes Breakthrough


Amyloid could "directly poison" pancreas cells. Shedding light on how a
malfunctioning protein helps trigger Type 2 diabetes could one day offer the
chance to halt the damage, say scientists.. 


Advertisement 





The presence of amyloid protein may produce a chain reaction which destroys
vital insulin-producing cells. Researchers based in Dublin, Ireland, writing
in the Nature Immunology, say future drugs could target this process.
Amyloid is implicated in many other diseases, most notably Alzheimer's. 

Scientists at Trinity College Dublin have discovered what could be the
underlying basis for Type 2 diabetes, a debilitating disease where people
stop responding to insulin.  The TCD team has found that the peptide
hormone, Islet Amyloid Polypeptide (IAPP), which gets deposited in the
pancreas in Type 2 diabetes, is the trigger for a protein complex called the
inflammasome.  This in turn leads to the production of the pro-inflammatory
agent IL-1beta, which is already being targeted in several clinical trials.


"We've found what might be the 'straw that breaks the camel's back' in Type
2 diabetes," says Dr. Seth Masters, lead author on the publication.
"IL-1beta is known to be important in the disease and we have found what
might be the key mechanism leading to its over-production." The work
provides a deeper insight into the disease process. 

"Current treatments are somewhat effective but there is a pressing need for
newer therapeutic approaches," says Professor of Biochemistry, Luke O'Neill,
who heads the group at TCD.  "IL-1beta is being explored by several drug
companies and results are promising.  Our work confirms the importance of
IL-1beta in the disease and also points to Nlrp3 as a new target to go
after." 

Insulin is made in "beta cells" in the pancreas, and scientists first
noticed "deposits" of the amyloid protein in pancreatic tissue of some
people with Type 2 diabetes some years ago.

It was thought that amyloid could be poisoning the cells directly, but the
latest research offers an additional explanation. It found that a type of
immune cell called a macrophage, whose normal role is to get rid of debris
in the cell, reacted abnormally when it ingested amyloid.

It triggered activity in other cells nicknamed "angry macrophages," which in
turn released proteins that cause inflammation. The inflammation then
destroys the vital beta cells, and the ability to produce insulin is
reduced.

Opsona Therapeutics, co-founded by Luke O'Neill, has an active program in
this area. The work is likely to spur further efforts to develop drugs that
interfere with this process.  "Mechanistic insights such as the one we have
made are very important for the effort to develop new therapies. There is
real optimism that much better treatments for Type 2 diabetes will emerge
from this area," says Prof. O'Neill.  

The researchers said that they hoped the finding would "spur new research"
to target the mechanisms of the disease. 

Dr. Eric Hewitt, a researcher into amyloid-related disease at Leeds
University, U.K., said the paper was "interesting," and could help explain
why the presence of amyloid deposits, or the process that laid them down,
could be so damaging. "It suggests we are looking at a very complex disease
-- we know that amyloid is present in some Type 2 diabetics, but not
others.. What we have is a second indirect mechanism which can lead to the
destruction of beta cells, and this could be helpful when looking at other
diseases which may involve amyloid, such as Alzheimer's.. It does offer a
possible opportunity to interrupt this mechanism at some point in the future
and perhaps stop the disease from progressing."

 

-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://www.acb.org/pipermail/acb-diabetics/attachments/20101218/aa41783c/attachment-0001.htm>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: not available
Type: application/octet-stream
Size: 43 bytes
Desc: not available
URL: <http://www.acb.org/pipermail/acb-diabetics/attachments/20101218/aa41783c/attachment-0002.obj>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: not available
Type: application/octet-stream
Size: 3072 bytes
Desc: not available
URL: <http://www.acb.org/pipermail/acb-diabetics/attachments/20101218/aa41783c/attachment-0003.obj>